TruBridge 향후 성장
Future 기준 점검 3/6
TruBridge (는) 각각 연간 25% 및 4.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 32.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 5.3% 로 예상됩니다.
핵심 정보
25.0%
이익 성장률
32.73%
EPS 성장률
| Healthcare Services 이익 성장 | 21.7% |
| 매출 성장률 | 4.8% |
| 향후 자기자본이익률 | 5.31% |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 15 May 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Apr 17
TBRG: Potential IKS Deal And EHR Execution Will Shape Future Re Rating
TruBridge's analyst fair value estimate has shifted from $21.00 to $22.00 as analysts update their models around potential IKS-related opportunities, as well as recent mixed price target moves across the Street. Analyst Commentary Bullish Takeaways Bullish analysts point to the potential IKS transaction as aligned with TruBridge's ongoing review of its business.
새로운 내러티브 • Apr 16
AI And Global Delivery Expansion Will Reshape Rural Hospital Solutions Over The Next Decade
Catalysts About TruBridge TruBridge provides revenue cycle, financial health and patient care software and services to hospitals, with a focus on rural and community facilities. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 14
TruBridge: Potential Takeover Target, Upside Fundamentally Supported
Summary TruBridge, Inc. is undergoing an operational turnaround with margin expansion, rising EBITDA, and a shift to high-quality recurring revenue. A potential $600 million takeover by Inventurus Knowledge Systems offers a 36–40% premium to current prices but introduces binary deal risk. TBRG’s recurring revenue remains high at 94%, with stable cash flows and improved profitability despite flat top-line growth. The implied takeover valuation aligns with sector multiples, suggesting the upside is fundamentally supported, not purely speculative. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 02
TBRG: Revenue Cycle Momentum And EHR Stability Will Support Future Re Rating
Analysts have trimmed their price targets on TruBridge, with the average moving from about $22.67 to $21.00 as they weigh a slightly higher discount rate, modestly different revenue growth and margin assumptions, and a lower future P/E multiple against the company's mix of Revenue Cycle Management growth potential and stable Electronic Health Records operations. Analyst Commentary Recent research updates on TruBridge reflect a mix of optimism around the business model and caution around execution and valuation.
새로운 내러티브 • Apr 02
AI Expansion And Global Delivery Shift Will Shape A Steady But Capped Future
Catalysts About TruBridge TruBridge provides revenue cycle, financial health and electronic health record solutions to hospitals and healthcare providers, with a particular focus on rural and community facilities. What are the underlying business or industry changes driving this perspective?분석 기사 • Feb 12
Returns At TruBridge (NASDAQ:TBRG) Appear To Be Weighed Down
What are the early trends we should look for to identify a stock that could multiply in value over the long term...내러티브 업데이트 • Jan 28
TBRG: Revenue Cycle Focus And EHR Stability Will Test Execution Outcomes
Narrative Update The analyst price target for TruBridge has shifted modestly higher to about $22.67 per share, supported by analysts citing the potential of its Revenue Cycle Management focus alongside a steadier Electronic Health Records business, while still calling out execution risk after recent periods of low growth. Analyst Commentary Recent research points to a mixed but constructive view on TruBridge, with analysts focusing on the shift toward Revenue Cycle Management and the steadier Electronic Health Records business when considering valuation and execution risk.내러티브 업데이트 • Jan 12
TBRG: Revenue Cycle Realignment And EHR Stability Will Require Steady Execution
Narrative Update The analyst price target for TruBridge now centers around US$23, a modest lift from the prior US$22.60. Analysts point to the potential of the Revenue Cycle Management opportunity alongside a steadier Electronic Health Records business, while still flagging execution risk after recent periods of low growth.내러티브 업데이트 • Dec 17
TBRG: Revenue Cycle Shift Will Demand Proven Execution Before Rerating
Analysts raised their price target on TruBridge modestly, citing improving growth prospects from the company’s shift toward revenue cycle management as evidence builds of its long-term earnings potential. Analyst Commentary Bullish Takeaways Bullish analysts view the company’s realignment toward revenue cycle management as a structurally higher growth opportunity compared with its legacy clinical software offerings.내러티브 업데이트 • Dec 03
TBRG: Revenue Cycle Pivot Will Require Clear Execution Evidence In 2025
Analysts have nudged their price target on TruBridge slightly higher to approximately $22.60 per share. This reflects increased confidence that the company’s shift toward revenue cycle management can unlock more attractive, evidence-based growth than its legacy clinical software focus.내러티브 업데이트 • Nov 19
TBRG: Measured Optimism Will Depend On Evidence Of Execution In 2025
TruBridge's analyst price target has been revised downward from $24.75 to $22.60. Analysts cite recent coverage reflecting cautious optimism about the company's strategic shift toward revenue cycle management, while awaiting clearer evidence of execution before turning more positive.분석 기사 • Nov 14
Solid Earnings Reflect TruBridge's (NASDAQ:TBRG) Strength As A Business
Even though TruBridge, Inc.'s ( NASDAQ:TBRG ) recent earnings release was robust, the market didn't seem to notice. We...내러티브 업데이트 • Aug 15
AI And India Hub Will Boost Future Healthcare Efficiency
Despite a notable improvement in TruBridge’s net profit margin and a significant decline in its future P/E ratio, the consensus analyst price target has been sharply revised down from $29.25 to $24.75. What's in the News TruBridge lowered its full-year 2025 revenue guidance to $345 million-$350 million from a previous range of $345 million-$360 million; third quarter 2025 revenue is forecasted at $85 million-$87 million.새로운 내러티브 • May 31
Digital Automation And AI Will Drive Healthcare Transformation
Increased AI-driven automation, expanded SaaS offerings, and digital transformation are expected to boost operational efficiency, recurring revenue growth, and earnings quality.분석 기사 • Feb 14
Would TruBridge (NASDAQ:TBRG) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Jan 17
TruBridge, Inc. (NASDAQ:TBRG) Shares Fly 27% But Investors Aren't Buying For Growth
TruBridge, Inc. ( NASDAQ:TBRG ) shares have continued their recent momentum with a 27% gain in the last month alone...분석 기사 • Nov 13
TruBridge, Inc.'s (NASDAQ:TBRG) Business And Shares Still Trailing The Industry
TruBridge, Inc.'s ( NASDAQ:TBRG ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a buy right now...분석 기사 • Aug 05
Is TruBridge (NASDAQ:TBRG) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • May 25
Is TruBridge, Inc. (NASDAQ:TBRG) Trading At A 38% Discount?
Key Insights The projected fair value for TruBridge is US$16.15 based on 2 Stage Free Cash Flow to Equity Current share...분석 기사 • Feb 23
Computer Programs and Systems (NASDAQ:CPSI) Might Be Having Difficulty Using Its Capital Effectively
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...분석 기사 • Sep 06
What Does Computer Programs and Systems, Inc.'s (NASDAQ:CPSI) Share Price Indicate?
Computer Programs and Systems, Inc. ( NASDAQ:CPSI ), is not the largest company out there, but it received a lot of...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 407 | 16 | N/A | N/A | 1 |
| 12/31/2027 | 371 | 16 | 36 | 63 | 5 |
| 12/31/2026 | 351 | 26 | 30 | 57 | 2 |
| 3/31/2026 | 346 | 4 | 30 | 47 | N/A |
| 12/31/2025 | 347 | 4 | 20 | 37 | N/A |
| 9/30/2025 | 347 | 3 | 21 | 37 | N/A |
| 6/30/2025 | 345 | -11 | 16 | 34 | N/A |
| 3/31/2025 | 345 | -18 | 22 | 39 | N/A |
| 12/31/2024 | 342 | -20 | 13 | 31 | N/A |
| 9/30/2024 | 337 | -59 | -10 | 10 | N/A |
| 6/30/2024 | 335 | -54 | -18 | 3 | N/A |
| 3/31/2024 | 334 | -52 | -33 | -10 | N/A |
| 12/31/2023 | 337 | -47 | -22 | -1 | N/A |
| 9/30/2023 | 337 | -1 | -7 | 15 | N/A |
| 6/30/2023 | 337 | 5 | 1 | 23 | N/A |
| 3/31/2023 | 335 | 11 | 9 | 30 | N/A |
| 12/31/2022 | 327 | 16 | 13 | 32 | N/A |
| 9/30/2022 | 317 | 18 | 26 | 43 | N/A |
| 6/30/2022 | 305 | 19 | 19 | 34 | N/A |
| 3/31/2022 | 290 | 22 | 33 | 46 | N/A |
| 12/31/2021 | 281 | 18 | 37 | 48 | N/A |
| 9/30/2021 | 273 | 16 | 42 | 51 | N/A |
| 6/30/2021 | 272 | 18 | 51 | 57 | N/A |
| 3/31/2021 | 263 | 14 | 50 | 55 | N/A |
| 12/31/2020 | 264 | 14 | 42 | 49 | N/A |
| 9/30/2020 | 268 | 22 | 45 | 51 | N/A |
| 6/30/2020 | 269 | 20 | 46 | 51 | N/A |
| 3/31/2020 | 275 | 20 | 39 | 43 | N/A |
| 12/31/2019 | 275 | 20 | N/A | 44 | N/A |
| 9/30/2019 | 276 | 16 | N/A | 35 | N/A |
| 6/30/2019 | 277 | 18 | N/A | 34 | N/A |
| 3/31/2019 | 279 | 17 | N/A | 29 | N/A |
| 12/31/2018 | 280 | 17 | N/A | 24 | N/A |
| 9/30/2018 | 286 | -11 | N/A | 20 | N/A |
| 6/30/2018 | 284 | -15 | N/A | 16 | N/A |
| 3/31/2018 | 284 | -13 | N/A | 17 | N/A |
| 12/31/2017 | 277 | -17 | N/A | 24 | N/A |
| 9/30/2017 | 263 | 6 | N/A | 23 | N/A |
| 6/30/2017 | 261 | 5 | N/A | 26 | N/A |
| 3/31/2017 | 262 | 6 | N/A | 11 | N/A |
| 12/31/2016 | 267 | 4 | N/A | 2 | N/A |
| 9/30/2016 | 247 | 5 | N/A | 2 | N/A |
| 6/30/2016 | 227 | 7 | N/A | 5 | N/A |
| 3/31/2016 | 206 | 11 | N/A | 18 | N/A |
| 12/31/2015 | 182 | 18 | N/A | 31 | N/A |
| 9/30/2015 | 184 | 21 | N/A | 39 | N/A |
| 6/30/2015 | 193 | 27 | N/A | 42 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: TBRG 의 연간 예상 수익 증가율(25%)이 saving rate(3.5%)보다 높습니다.
수익 vs 시장: TBRG 의 연간 수익(25%)이 US 시장(16.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 수익: TBRG 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.
수익 대 시장: TBRG 의 수익(연간 4.8%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: TBRG 의 수익(연간 4.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: TBRG의 자본 수익률은 3년 후 5.3%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 18:10 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
TruBridge, Inc.는 23명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Matthew Gillmor | Baird |
| Stephanie Davis | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |